Altimmune (Altimmune) FCF Margin % : -44,683.78% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Altimmune FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Altimmune's Free Cash Flow for the three months ended in Dec. 2023 was $-16.53 Mil. Altimmune's Revenue for the three months ended in Dec. 2023 was $0.04 Mil. Therefore, Altimmune's FCF Margin % for the quarter that ended in Dec. 2023 was -44,683.78%.

As of today, Altimmune's current FCF Yield % is -16.81%.

The historical rank and industry rank for Altimmune's FCF Margin % or its related term are showing as below:

ALT' s FCF Margin % Range Over the Past 10 Years
Min: -17806.81 Med: -177.91 Max: 92223.53
Current: -17806.81

During the past 13 years, the highest FCF Margin % of Altimmune was 92223.53%. The lowest was -17806.81%. And the median was -177.91%.

ALT's FCF Margin % is ranked worse than
93.71% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs ALT: -17806.81

Altimmune FCF Margin % Historical Data

The historical data trend for Altimmune's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune FCF Margin % Chart

Altimmune Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-166.02

-423.31

-2,053.29

92,223.53

-17,806.81

Altimmune Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															15,767.27	-92,657.14	-322,983.33	-5,659.39	-44,683.78

Competitive Comparison of Altimmune's FCF Margin %

For the Biotechnology subindustry, Altimmune's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altimmune's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Altimmune's FCF Margin % falls into.

Altimmune FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Altimmune's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-75.857	/	0.426
	=	-17,806.81 %

Altimmune's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-16.533	/	0.037
	=	-44,683.78 %

Altimmune FCF Margin % Related Terms

Thank you for viewing the detailed overview of Altimmune's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune (Altimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ALT1:Mexico 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Executives

David Drutz	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris	officer: Chief Medical Officer	C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt	officer: Chief Business Officer	ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg	director, officer: President and CEO	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill	director	C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts	officer: Chief Scientific Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges	director	19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018